Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Neoplasms 2Neoplasm Metastasis 2Nelson Syndrome 2Multiple Myeloma 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neuroectodermal Tumors, Primitive 1

Interventions

telotristat ethyl 5lanreotide 2telotristat 1pasireotide 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Random Allocation 1Panitumumab 1Octreotide 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Serotonin Syndrome × pasireotide × Clear all
NCT00088595 2012-06-04

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Novartis

Phase 2 Completed
45 enrolled 10 charts
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡